高级检索
    评价者：姚和瑞, 游凯云, 文献合成者：汪颖, 余运芳. CALGB 40603研究分析: Ⅱ/Ⅲ期三阴性乳腺癌新辅助化疗加用卡铂和/或贝伐单抗提高病理完全缓解率[J]. 循证医学, 2017, 17(3): 140-145. DOI: 10.12019/j.issn.1671-5144.2017.03.006
    引用本文: 评价者：姚和瑞, 游凯云, 文献合成者：汪颖, 余运芳. CALGB 40603研究分析: Ⅱ/Ⅲ期三阴性乳腺癌新辅助化疗加用卡铂和/或贝伐单抗提高病理完全缓解率[J]. 循证医学, 2017, 17(3): 140-145. DOI: 10.12019/j.issn.1671-5144.2017.03.006
    shu
    Reviewers： YAO He-rui, You Kai-yun, WANG Ying, Literature Co-workers： YU Yun-fang. The Interpretation of CALGB 40603 Trial: The Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Chemotherapy Improve Pathologic Complete Response Rates in StageⅡto Ⅲ Triple Negative Breast Cancer[J]. Journal of Evidence-Based Medicine, 2017, 17(3): 140-145. DOI: 10.12019/j.issn.1671-5144.2017.03.006
    Citation: Reviewers： YAO He-rui, You Kai-yun, WANG Ying, Literature Co-workers： YU Yun-fang. The Interpretation of CALGB 40603 Trial: The Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Chemotherapy Improve Pathologic Complete Response Rates in StageⅡto Ⅲ Triple Negative Breast Cancer[J]. Journal of Evidence-Based Medicine, 2017, 17(3): 140-145. DOI: 10.12019/j.issn.1671-5144.2017.03.006
    shu

    CALGB 40603研究分析: Ⅱ/Ⅲ期三阴性乳腺癌新辅助化疗加用卡铂和/或贝伐单抗提高病理完全缓解率

    The Interpretation of CALGB 40603 Trial: The Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Chemotherapy Improve Pathologic Complete Response Rates in StageⅡto Ⅲ Triple Negative Breast Cancer

      摘要
      • HTML全文
      • 参考文献(9)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回